titoli, abstracts, parole chiave >>>
Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study

Arru, Giannina and Leoni, Stefania and Pugliatti, Maura and Mei, Alessandra and Serra, Caterina and Delogu, Lucia Gemma and Manetti, Roberto and Dolei, Antonina and Sotgiu, Stefano and Mameli, Giuseppe (2014) Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study. Multiple Sclerosis Journal, Vol. 20 (2), p. 174-182. ISSN 1352-4585. eISSN 1477-0970. Article.

Full text not available from this repository.

DOI: 10.1177/1352458513494957

Abstract

Background: Several viruses were reported as co-factors triggering the pathogenesis of multiple sclerosis (MS), including the endogenous retroviruses of the HERV-W family, that were also proposed as biomarkers of disease progression and therapy outcome.
Objective: The objective of this article is to clarify whether in MS patients treatment with natalizumab has effects on MSRV/syncytin-1/HERV-W expression and the possible relationship with disease outcome.
Methods: Peripheral blood mononuclear cells were collected from 22 patients with relapsing–remitting disease, at entry and after three, six and 12 months of treatment with natalizumab. The cell subpopulations and the expression of MSRVenv/syncytin-1/HERV-Wenv were analyzed by flow cytometry and by discriminatory env-specific RT-PCR assays.
Results: By flow cytometry the relative amounts of T, NK and monocyte subpopulations were shown to remain fairly constant. A relative increase of B lymphocytes was observed at three to six months (p = 0.033). The MSRVenv and syncitin-1 transcripts were reduced at six to 12 months of therapy (p = 0.0001). Accordingly, at month 12, the plasma-membrane levels of the HERV-Wenv protein were reduced (p = 0.0001). B cells, NK and monocytes but not T cells expressed the HERV-Wenv protein. None of the patients relapsed during therapy.
Conclusion: Effective therapy with natalizumab downregulates MSRV/syncytin-1/HERV-W expression.

Item Type:Article
ID Code:10711
Status:Published
Refereed:Yes
Uncontrolled Keywords:Multiple sclerosis, natalizumab, MSRV/syncytin-1/HERV-W
Subjects:Area 06 - Scienze mediche > MED/39 Neuropsichiatria infantile
Area 06 - Scienze mediche > MED/07 Microbiologia e microbiologia clinica
Area 06 - Scienze mediche > MED/26 Neurologia
Area 06 - Scienze mediche > MED/09 Medicina interna
Divisions:001 Università di Sassari > 02 Centri > Centro di eccellenza interdisc. sviluppo ricerca biotecnologica e studio biodiversità della Sardegna e dell'area mediterranea
001 Università di Sassari > 01-a Nuovi Dipartimenti dal 2012 > Scienze Biomediche
001 Università di Sassari > 01-a Nuovi Dipartimenti dal 2012 > Chimica e Farmacia
001 Università di Sassari > 01-a Nuovi Dipartimenti dal 2012 > Medicina Clinica e Sperimentale
Publisher:SAGE Publications
ISSN:1352-4585
eISSN:1477-0970
Deposited On:17 Feb 2015 11:26

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page